Dersimelagon (MT-7117)

Name: Dersimelagon (MT-7117) in Erythropoietic protoporphyria or X-linked protoporphyria: Disease description
Published: 2026-09-21T21:42:40-04:00

Erythropoietic protoporphyria or X-linked protoporphyria

Manufacturer: LEO Pharma
Regulatory submission: NDA submitted June 2026
Launch: Potential launch in 2027
Last updated: September 21, 2026

Section

Product information and disease description Place of product in therapy

Disease description

71 evidence topics · 34 sources

Definition and etiology8 evidence topics · 5 sources
Epidemiology11 evidence topics · 11 sources
Natural history, survival, and mortality6 evidence topics · 6 sources
Pathophysiology6 evidence topics · 5 sources
Diagnosis6 evidence topics · 8 sources
Clinical presentation - signs and symptoms9 evidence topics · 12 sources
Long-term morbidity5 evidence topics · 5 sources
Burden of Erythropoietic protoporphyria or X-linked protoporphyria20 evidence topics · 14 sources